Logo

Galderma Reports Results of Nemolizumab in P-III (OLYMPIA 2) Trial for the Treatment of Prurigo Nodularis

Share this
Galderma Reports Results of Nemolizumab in P-III (OLYMPIA 2) Trial for the Treatment of Prurigo Nodularis

Galderma Reports Results of Nemolizumab in P-III (OLYMPIA 2) Trial for the Treatment of Prurigo Nodularis

Shots:

  • The P-III (OLYMPIA 2) trial evaluating the efficacy, safety, PK & immunogenicity of nemolizumab as monothx. vs PBO in 540 patients aged 18yrs. with PN after 16wk. treatment period
  • The trial met all 1EPs & 2EPs i.e., 38% vs 11% of patients showed clearance or almost-clearance of skin lesions as assessed by using the IGA score, 56% vs 21% achieved a 4-point reduction in itch as measured by PP-NRS score. The safety profile was consistent with the P-II trial results
  • Nemolizumab also showed a positive benefit-risk balance & has been approved in Japan for pruritus associated with AD and is under clinical development in many countries globally. The therapy has received BTD from the US FDA for pruritus associated PN

Ref: Galderma | Image: Galderma

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions